KLRS

Business Context and Reporting Period

Company: Kalaris Therapeutics, Inc. (KLRS)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Kalaris is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company's primary asset is TH103, a novel anti-VEGF drug candidate designed for extended intraocular retention to treat neovascular Age-related Macular Degeneration (nAMD).
Corporate Structure: The company was formed via a reverse recapitalization merger with AlloVir, Inc., consummated on March 18, 2025. Legacy Kalaris is the accounting acquirer. The company is classified as a "smaller reporting company" and a "controlled company" due to significant ownership by Samsara BioCapital, LP.

Key Financial Metrics

Note: The company has not generated any revenue from product sales. The significant increase in cash position in 2025 was driven by the Merger (approx. $102.1 million) and a private placement (approx. $50.0 million).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $25.7 million year-over-year. This improvement was primarily driven by a $37.8 million reduction in "Loss on extinguishment and on issuance of convertible promissory notes" and a $32.1 million decrease in "License fees, milestone payments and annual maintenance fees" (specifically related to a one-time royalty obligation expense recorded in 2024).
• Operating Expenses: Total operating expenses decreased by $5.6 million. Research and Development (R&D) expenses declined by $14.3 million due to the absence of the 2024 royalty obligation charge, partially offset by a $14.8 million increase in external CDMO/CRO costs as clinical trials advanced. General and Administrative (G&A) expenses increased by $8.7 million due to higher professional fees, insurance costs, and personnel expenses following the Merger.
• Liquidity: Cash and cash equivalents increased from $1.6 million in 2024 to $118.0 million in 2025, providing a runway into the fourth quarter of 2027 based on current operating plans.

Guidance, Outlook, and Risks

Clinical Outlook

• Phase 1a Results: Initial data from the Phase 1a single ascending dose trial (announced Dec 2025) showed TH103 was generally well-tolerated with improvements in visual acuity and anatomical outcomes. However, cases of intraocular inflammation (IOI) were observed, linked to host cell protein impurities. Manufacturing processes have been refined to reduce these impurities.
• Phase 1b/2 Status: The company is currently conducting a Phase 1b/2 multiple ascending dose trial. Preliminary data is expected in the first half of 2027.
• Phase 3 Timeline: Assuming successful Phase 1b/2 results, the company intends to initiate Phase 3 trials by year-end 2027.

Management Commentary

Management expects to continue incurring significant expenses and operating losses for the foreseeable future. The company anticipates substantial increases in expenses as it advances clinical trials, expands its corporate infrastructure, and prepares for potential commercialization.

Key Risks and Contingencies

• Internal Controls: The company has identified material weaknesses in its internal control over financial reporting as of December 31, 2024, which remain unremediated as of December 31, 2025. These weaknesses relate to the control environment, risk assessment, and monitoring activities.
• Manufacturing & Safety: Observed IOI events in clinical trials are linked to manufacturing impurities. While process refinements are underway, failure to eliminate these issues could delay development.
• Capital Requirements: The company will require substantial additional funding to continue operations. Failure to raise capital could force delays or termination of development programs.
• Legal Proceedings: Two complaints have been filed by purported AlloVir stockholders regarding the Merger proxy statement, alleging negligent misrepresentation. The company denies these allegations.

Investor Verification Checklist

• Manufacturing Refinements: Verify the efficacy of the new manufacturing processes in eliminating host cell protein impurities and preventing future intraocular inflammation (IOI) events in the ongoing Phase 1b/2 trial.
• Internal Control Remediation: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.
• Cash Burn Rate: Track the actual cash burn rate against the projected runway into Q4 2027, given the high costs of clinical development.
• Phase 1b/2 Data: Await the preliminary data release expected in the first half of 2027 to assess the durability and safety profile of TH103 with the refined manufacturing process.
• Legal Status: Monitor the status of the pending litigation regarding the Merger proxy statement.